Evidence map›Paper›PMID 20531016›Full record

ArticleJournal of acquired immune deficiency syndromes (1999)2010

Pseudovirion particles bearing native HIV envelope trimers facilitate a novel method for generating human neutralizing monoclonal antibodies against HIV.

Mark D Hicar, Xuemin Chen, Bryan Briney, Jason Hammonds, Jaang-Jiun Wang, Spyros Kalams, Paul W Spearman, James E Crowe

Abstract read
In one paragraph

Article in Journal of acquired immune deficiency syndromes (1999), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
1.3field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Mark D HicarDepartment of Pediatrics, Vanderbilt University Medical Center, Nashville, TN 37232-2905, USA.
Xuemin Chen
Bryan Briney
Jason Hammonds
Jaang-Jiun Wang
Spyros Kalams
Paul W Spearman
James E Crowe
Vanderbilt University Medical Center · USEmory University · USChildren's Healthcare of Atlanta · US

Funding

Virology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Carlos del Rio · 2002 to 2026
$74.0M
VIROLOGY COREP30AI054999 · NIAID · VANDERBILT UNIVERSITY · PI D'AQUILA, RICHARD · 2003 to 2011
$10.3M
Clonal Analysis of the Human B Cell Response to HIVU01AI078407 · NIAID · VANDERBILT UNIVERSITY · PI CROWE, JAMES E · 2008 to 2012
$3.9M
Alphavirus-based Vaccine for Prevention of MPV InfectionR01AI059597 · NIAID · VANDERBILT UNIVERSITY · PI CROWE, JAMES E · 2005 to 2008
$1.6M
Antibodies Recognizing Quaternary Differences in HIV Envelope Glycoproteins (K08)K08AI083078 · NIAID · VANDERBILT UNIVERSITY · PI HICAR, MARK DANIEL · 2009 to 2013
$639k
NIAID NIH HHS K08 AI083078NIAID NIH HHS P30 AI050409NIAID NIH HHS P30 AI-054999NIAID NIH HHS P30 AI054999NIAID NIH HHS P30-AI50409NIAID NIH HHS R01 AI059597NIAID NIH HHS U01 AI-078407NIAID NIH HHS U01 AI078407
6 · The paper itself

Abstract

Monomeric HIV envelope vaccines fail to elicit broadly neutralizing antibodies or to protect against infection. Neutralizing antibodies against HIV bind to native functionally active Env trimers on the virion surface. Gag-Env pseudovirions recapitulate the native trimer and could serve as an effective epitope presentation platform for study of the neutralizing antibody response in HIV-infected individuals. To address if pseudovirions can recapitulate native HIV virion epitope structures, we carefully characterized these particles, concentrating on the antigenic structure of the coreceptor binding site. By blue native gel shift assays, Gag-Env pseudovirions were shown to contain native trimers that were competent for binding to neutralizing monoclonal antibodies. In enzyme-linked immunosorbent assay, pseudovirions exhibited increased binding of known CD4-induced antibodies after addition of CD4. Using flow cytometric analysis, fluorescently labeled pseudovirions specifically identified a subset of antigen-specific B cells in HIV-infected subjects. Interestingly, the sequence of one of these novel human antibodies, identified during cloning of single HIV-specific B cells and designated 2C6, exhibited homology to mAb 47e, a known anti-CD4-induced coreceptor binding site antibody. The secreted monoclonal antibody 2C6 did not bind monomeric gp120, but specifically bound envelope on pseudovirions. A recombinant form of the antibody 2C6 acted as a CD4-induced epitope-specific antibody in neutralization assays, yet did not bind monomeric gp120. These findings imply specificity against a quaternary epitope presented on the pseudovirion envelope spike. These data demonstrate that Gag-Env pseudovirions recapitulate CD4 and coreceptor binding pocket antigenic structures and can facilitate identification of B-cell clones that secrete neutralizing antibodies.

Indexed as

AIDS VaccinesAmino Acid SequenceAntibodies, MonoclonalAntibody SpecificityAntigens, CD19B-LymphocytesCells, Culturedenv Gene Products, Human Immunodeficiency Virusgag Gene Products, Human Immunodeficiency VirusGene Expression RegulationGreen Fluorescent ProteinsHIVHumansHybridomasImmunoglobulinsMolecular Sequence DataAIDS VaccinesAntibodies, MonoclonalAntigens, CD19env Gene Products, Human Immunodeficiency Virusgag Gene Products, Human Immunodeficiency VirusGreen Fluorescent ProteinsImmunoglobulins

Identifiers

PMID20531016
PMCPMC2930513
OpenAlexW2028888271

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.